Man will always be faced with disease and the need to discover new drugs is a constant battle for scientists especially since the process of identifying suitable drug candidates takes a long time. Drug discovery research involves studying the effects the drug has on the body (pharmacodynamics) as well as studying what the body does to the drug (pharmacokinetics). An important and vital aspect of any rational drug discovery research project is to study its pharmacokinetics (PK) by investigating the Absorption, Distribution, Metabolism and Excretion (ADME) of the pharmaceutical compound. ADME is a discipline of the study of drug metabolism and pharmacokinetics abbreviated as DMPK. DMPK involves looking at the ADME of drugs in animals and humans so as to prevent lots of time and money being spent on investigating drug compounds that are toxic to man.
It is crucial for pharmaceutical developers to identify viable drug candidates in a short turnover time and NoAb BioDiscoveries is the research facility to turn to for accelerated drug discovery processes and innovative tools that focuses on lead selection and optimization. By offering a number of specialized and proprietary research services that include in vitro ADME assays, in vivo PK, bioanalysis and gene expression assays, NoAb BioDiscoveries is able to provide DMPK services that allow the profiling of compounds for selection of the best candidates for further pre-clinical and clinical development. DMPK is important to generate data to explain any toxicity effects or efficacy problems and aids in the planning of drug-drug interactions for advancement into phase I clinical trials. NoAb BioDiscoveries has experienced scientists who consistently develop innovative tools and technologies that better characterize DMPK enabling the optimization of lead selection while accelerating the drug development process. You can be assured that with NoAb BioDiscoveries, the data generated is accurate and the leads selected are the best candidates for further drug development.
DMPK at NoAb BioDiscoveries is carried out by designing the best strategies and protocols to suit individual needs for any drug discovery research. Though standard DMPK studies are skillfully designed and performed, scientists at NoAb BioDiscoveries customize the in vitro and in vivo assays to your specifications. Studies typically involve the use of fully conscious animals that have been appropriately catheterized for drug administration and sample collection. All DMPK studies are carried out in-house under strict guidelines by highly trained and experienced scientists. You can be assured of quality, timely and efficient service! For a detailed outline of the various PK and ADME assay services available from this remarkable research facility, please visit www.noabbiodiscoveries.com and browse through the discovery services on offer.
Any pharmaceutical developer knows that DMPK studies are vital to identify viable drug candidates by studying the pharmacodynamics and pharmacokinetics of the pharmaceutical compound. With a continuous provision of advanced research tools that better characterize properties of drug candidates, NoAb BioDiscoveries has helped to shape and optimize drug discovery research for all its clients. The commitment to accelerate the drug discovery process while reducing costs and maximizing profits and to provide accurate and reliable results using superior scientific procedures makes NoAb BioDiscoveries a cutting edge provider of discovery services. Visit www.noabbiodiscoveries.com and become a leading pharmaceutical developer with NoAb BioDiscoveries by your side!
